Literature DB >> 24196915

How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective.

Vikas Prasad1, Winfried Brenner, Irvin M Modlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24196915     DOI： 10.1007/s00259-013-2593-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  14 in total

1.  Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

Authors:  Joyce A O'Shaughnessy; Gary J Kelloff; Gary B Gordon; Andrew J Dannenberg; Waun Ki Hong; Carol J Fabian; Caroline C Sigman; Monica M Bertagnolli; Steven P Stratton; Stephen Lam; William G Nelson; Frank L Meyskens; David S Alberts; Michele Follen; Anil K Rustgi; Vali Papadimitrakopoulou; Peter T Scardino; Adi F Gazdar; Lee W Wattenberg; Michael B Sporn; Wael A Sakr; Scott M Lippman; Daniel D Von Hoff
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

2.  Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.

Authors:  Andreas Klaus Pfeifer; Tine Gregersen; Henning Grønbæk; Carsten Palnæs Hansen; Jan Müller-Brand; Karin Herskind Bruun; Klaus Krogh; Andreas Kjær; Ulrich Knigge
Journal:  Neuroendocrinology       Date:  2011-02-19       Impact factor: 4.914

3.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

Authors:  Anna Imhof; Philippe Brunner; Nicolas Marincek; Matthias Briel; Christian Schindler; Helmut Rasch; Helmut R Mäcke; Christoph Rochlitz; Jan Müller-Brand; Martin A Walter
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

4.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

5.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.

Authors:  Dik J Kwekkeboom; Eric P Krenning; Rachida Lebtahi; Paul Komminoth; Beata Kos-Kudła; Wouter W de Herder; Ursula Plöckinger
Journal:  Neuroendocrinology       Date:  2009-08-28       Impact factor: 4.914

6.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

7.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

8.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

9.  Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.

Authors:  Amir Sabet; Torjan Haslerud; Ulrich-Frank Pape; Amin Sabet; Hojjat Ahmadzadehfar; Frank Grünwald; Stefan Guhlke; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-13       Impact factor: 9.236

Review 10.  Exosomes in tumor microenvironment influence cancer progression and metastasis.

Authors:  Christoph Kahlert; Raghu Kalluri
Journal:  J Mol Med (Berl)       Date:  2013-03-22       Impact factor: 4.599
View more
  5 in total

1.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Authors:  Rudolf A Werner; Thorsten Derlin; Steven P Rowe; Lena Bundschuh; Gabriel T Sheikh; Martin G Pomper; Sebastian Schulz; Takahiro Higuchi; Andreas K Buck; Frank M Bengel; Ralph A Bundschuh; Constantin Lapa
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

2.  Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.

Authors:  Stefano Severi; Maddalena Sansovini; Annarita Ianniello; Lisa Bodei; Silvia Nicolini; Toni Ibrahim; Valentina Di Iorio; Vincenzo D'Errico; Paola Caroli; Manuela Monti; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-26       Impact factor: 9.236

Review 3.  Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives.

Authors:  Nader Hirmas; Raya Jadaan; Akram Al-Ibraheem
Journal:  Nucl Med Mol Imaging       Date:  2018-03-28

Review 4.  68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.

Authors:  Rudolf A Werner; Christina Bluemel; Martin S Allen-Auerbach; Takahiro Higuchi; Ken Herrmann
Journal:  Ann Nucl Med       Date:  2014-08-20       Impact factor: 2.668

Review 5.  Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life.

Authors:  Stefano Severi; Ilaria Grassi; Silvia Nicolini; Maddalena Sansovini; Alberto Bongiovanni; Giovanni Paganelli
Journal:  Onco Targets Ther       Date:  2017-01-27       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.